Pravin R. Chaturvedi - Mar 1, 2022 Form 3 Insider Report for Jaguar Health, Inc. (JAGX)

Role: Chief Scientific Officer
Signature: /s/ Pravin Chaturvedi
Stock symbol: JAGX
Transactions as of: Mar 1, 2022
Transactions value $: $0
Form type: 3
Date filed: 3/29/2022, 04:30 PM
Next filing: Mar 30, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	JAGX	Stock Option (Right to Buy)							Mar 1, 2022	Common Stock	72.4K	$5.19	Direct	F1, F2, F3
holding	JAGX	Stock Option (Right to Buy)							Mar 1, 2022	Common Stock	15.8K	$1.34	Direct	F1, F4, F5
holding	JAGX	Stock Option (Right to Buy)							Mar 1, 2022	Common Stock	60K	$5.97	Direct	F1, F6, F7
holding	JAGX	Restricted stock units							Mar 1, 2022	Common Stock	30K		Direct	F1, F6, F8, F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Granted pursuant to the Issuer's 2014 Stock Incentive Plan.
F2	The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and Karen S. Wright, the former Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding followingthe issuer's underwritten public offering consummated on July 23, 2019. Mr. Bochnowski and Ms. Wright certified the exact number of option shares to be granted on 7/24/19, such that the effective date of the option grant was 7/24/19.
F3	Vests in equal monthly installments beginning on July 24, 2019, with three months of options, or 6,030 options, vested as of the grant date based on the reporting person's numberof years of employment with the issuer, such that the grant is vested in full on the 3-year anniversary of the grant date.
F4	The option grant was approved by the issuer's board of directors on March 20, 2020.
F5	The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.
F6	The option and restricted stock unit grants were approved by the issuer's board of directors on April 5, 2021.
F7	The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.
F8	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F9	The restricted stock units vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vestingdate or dates provided in the grant notice.